125 related articles for article (PubMed ID: 8143369)
21. Effect of continuous combined estrogen and desogestrel hormone replacement therapy on serum lipids and lipoproteins.
Marsh MS; Crook D; Whitcroft SI; Worthington M; Whitehead MI; Stevenson JC
Obstet Gynecol; 1994 Jan; 83(1):19-23. PubMed ID: 8272301
[TBL] [Abstract][Full Text] [Related]
22. [Effects of tamoxifen and estrogen replacement therapy on lipid metabolism and some other cardiovascular risk factors. A prospective study in hysterectomised women].
Imperato F; Marziani R; Perniola G; Ebano V; Fruscella M; Mossa B
Minerva Ginecol; 2003 Feb; 55(1):87-93. PubMed ID: 12598849
[TBL] [Abstract][Full Text] [Related]
23. Effect of tamoxifen on plasma lipids and lipoproteins in postmenopausal women with breast cancer.
Thangaraju M; Kumar K; Gandhirajan R; Sachdanandam P
Cancer; 1994 Feb; 73(3):659-63. PubMed ID: 8299087
[TBL] [Abstract][Full Text] [Related]
24. A two-year clinical study of the effects of two triphasic oral contraceptives on plasma lipids.
Kakis G; Powell M; Marshall A; Woutersz TB; Steiner G
Int J Fertil Menopausal Stud; 1994; 39(5):283-91. PubMed ID: 7820162
[TBL] [Abstract][Full Text] [Related]
25. The effect of tamoxifen treatment on serum cholesterol fractions in breast cancer women.
Dziewulska-Bokiniec A; Wojtacki J; Skokowski J; Kortas B
Neoplasma; 1994; 41(1):13-6. PubMed ID: 8202188
[TBL] [Abstract][Full Text] [Related]
26. Effects of tamoxifen treatment on plasma lipids and lipoprotein lipid composition.
Bagdade JD; Wolter J; Subbaiah PV; Ryan W
J Clin Endocrinol Metab; 1990 Apr; 70(4):1132-5. PubMed ID: 2318936
[TBL] [Abstract][Full Text] [Related]
27. Predictive value of remnant lipoprotein for cardiovascular events in patients with coronary artery disease after achievement of LDL-cholesterol goals.
Nakamura T; Obata JE; Hirano M; Kitta Y; Fujioka D; Saito Y; Kawabata K; Watanabe K; Watanabe Y; Mishina H; Kugiyama K
Atherosclerosis; 2011 Sep; 218(1):163-7. PubMed ID: 21605862
[TBL] [Abstract][Full Text] [Related]
28. Changes in serum lipid and lipoprotein levels in postmenopausal patients with node-positive breast cancer treated with tamoxifen.
Vrbanec D; Reiner Z; Belev B; Plestina S
Tumori; 1998; 84(6):687-90. PubMed ID: 10080678
[TBL] [Abstract][Full Text] [Related]
29. Effects of tamoxifen on serum lipid and apolipoprotein levels in postmenopausal patients with breast cancer.
Morales M; Santana N; Soria A; Mosquera A; Ordovás J; Nóvoa J; Betancor P; Valerón PF; Díaz-Chico B; Chirino R
Breast Cancer Res Treat; 1996; 40(3):265-70. PubMed ID: 8883969
[TBL] [Abstract][Full Text] [Related]
30. Testosterone enanthate at a dose of 200 mg/week decreases HDL-cholesterol levels in healthy men.
Meriggiola MC; Marcovina S; Paulsen CA; Bremner WJ
Int J Androl; 1995 Oct; 18(5):237-42. PubMed ID: 8567093
[TBL] [Abstract][Full Text] [Related]
31. Tamoxifen use, oestrogen binding and serum lipids in postmenopausal women with breast cancer.
Ingram D
Aust N Z J Surg; 1990 Sep; 60(9):673-5. PubMed ID: 2396945
[TBL] [Abstract][Full Text] [Related]
32. Serum lipoprotein responses during active and stable weight reduction in reproductive obese females.
Friedman CI; Falko JM; Patel ST; Kim MH; Newman HA; Barrows H
J Clin Endocrinol Metab; 1982 Aug; 55(2):258-62. PubMed ID: 7085852
[TBL] [Abstract][Full Text] [Related]
33. Serum lipids and lipoprotein disorders in cancer patients.
Alexopoulos CG; Blatsios B; Avgerinos A
Cancer; 1987 Dec; 60(12):3065-70. PubMed ID: 3677028
[TBL] [Abstract][Full Text] [Related]
34. Effects of soy bean on serum paraoxonase 1 activity and lipoproteins in hyperlipidemic postmenopausal women.
Shidfar F; Ehramphosh E; Heydari I; Haghighi L; Hosseini S; Shidfar S
Int J Food Sci Nutr; 2009 May; 60(3):195-205. PubMed ID: 18608549
[TBL] [Abstract][Full Text] [Related]
35. Effects of toremifene (TOR) and tamoxifen (TAM) on serum lipids in postmenopausal patients with breast cancer.
Kusama M; Miyauchi K; Aoyama H; Sano M; Kimura M; Mitsuyama S; Komaki K; Doihara H
Breast Cancer Res Treat; 2004 Nov; 88(1):1-8. PubMed ID: 15538040
[TBL] [Abstract][Full Text] [Related]
36. Effect of tamoxifen and transdermal hormone replacement therapy on cardiovascular risk factors in a prevention trial. Italian Chemoprevention Group.
Decensi A; Robertson C; Rotmensz N; Severi G; Maisonneuve P; Sacchini V; Boyle P; Costa A; Veronesi U
Br J Cancer; 1998 Sep; 78(5):572-8. PubMed ID: 9744493
[TBL] [Abstract][Full Text] [Related]
37. Tamoxifen therapy and hepatic steatosis.
Coskun U; Törüner FB; Günel N
Neoplasma; 2002; 49(1):61-4. PubMed ID: 12044063
[TBL] [Abstract][Full Text] [Related]
38. Increased plasma HDL-cholesterol and apo A-I in breast cancer patients undergoing adjuvant tamoxifen therapy.
Mastroianni A; Bellati C; Facchetti G; Oldani S; Franzini C; Berrino F
Clin Biochem; 2000 Aug; 33(6):513-6. PubMed ID: 11074246
[No Abstract] [Full Text] [Related]
39. Effects of tamoxifen on cardiovascular risk factors in postmenopausal women after 5 years of treatment.
Love RR; Wiebe DA; Feyzi JM; Newcomb PA; Chappell RJ
J Natl Cancer Inst; 1994 Oct; 86(20):1534-9. PubMed ID: 7932809
[TBL] [Abstract][Full Text] [Related]
40. Status of lipid and lipoprotein in female breast cancer patients at initial diagnosis and during chemotherapy.
Li X; Liu ZL; Wu YT; Wu H; Dai W; Arshad B; Xu Z; Li H; Wu KN; Kong LQ
Lipids Health Dis; 2018 Apr; 17(1):91. PubMed ID: 29678178
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
